Cargando…
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study
OBJECTIVES: To assess the humoral and cell-mediated response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited by the mRNA BNT162b2 vaccine in SARS-CoV-2-experienced and -naive subjects against a reference strain and SARS-CoV-2 variants. METHODS: The humoral response (includin...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464022/ https://www.ncbi.nlm.nih.gov/pubmed/34582981 http://dx.doi.org/10.1016/j.cmi.2021.09.016 |
_version_ | 1784572526149500928 |
---|---|
author | Cassaniti, Irene Bergami, Federica Percivalle, Elena Gabanti, Elisa Sammartino, Josè Camilla Ferrari, Alessandro Adzasehoun, Kodjo Messan Guy Zavaglio, Federica Zelini, Paola Comolli, Giuditta Sarasini, Antonella Piralla, Antonio Ricciardi, Alessandra Zuccaro, Valentina Maggi, Fabrizio Novazzi, Federica Simonelli, Luca Varani, Luca Lilleri, Daniele Baldanti, Fausto |
author_facet | Cassaniti, Irene Bergami, Federica Percivalle, Elena Gabanti, Elisa Sammartino, Josè Camilla Ferrari, Alessandro Adzasehoun, Kodjo Messan Guy Zavaglio, Federica Zelini, Paola Comolli, Giuditta Sarasini, Antonella Piralla, Antonio Ricciardi, Alessandra Zuccaro, Valentina Maggi, Fabrizio Novazzi, Federica Simonelli, Luca Varani, Luca Lilleri, Daniele Baldanti, Fausto |
author_sort | Cassaniti, Irene |
collection | PubMed |
description | OBJECTIVES: To assess the humoral and cell-mediated response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited by the mRNA BNT162b2 vaccine in SARS-CoV-2-experienced and -naive subjects against a reference strain and SARS-CoV-2 variants. METHODS: The humoral response (including neutralizing antibodies) and T-cell-mediated response elicited by BNT162b2 vaccine in 145 healthcare workers (both naive and positive for previous SARS-CoV-2 infection) were evaluated. In a subset of subjects, the effect of SARS-CoV-2 variants on antibody level and cell-mediated response was also investigated. RESULTS: Overall, 125/127 naive subjects (98.4%) developed both neutralizing antibodies and specific T cells after the second dose of vaccine. Moreover, the antibody and T-cell responses were effective against viral variants since SARS-CoV-2 NT Abs were still detectable in 55/68 (80.9%) and 25/29 (86.2%) naive subjects when sera were challenged against β and δ variants, respectively. T-cell response was less affected, with no significant difference in the frequency of responders (p 0.369). Of note, two doses of vaccine were able to elicit sustained neutralizing antibody activity against all the SARS-CoV-2 variants tested in SARS-CoV-2-experienced subjects. CONCLUSIONS: BNT162b2 vaccine elicited a sustained humoral and cell-mediated response in immunocompetent subjects after two-dose administration of the vaccine, and the response seemed to be less affected by SARS-CoV-2 variants, the only exceptions being the β and δ variants. Increased immunogenicity, also against SARS-CoV-2 variant strains, was observed in SARS-CoV-2-experienced subjects. These results suggest that triple exposure to SARS-CoV-2 antigens might be proposed as valuable strategy for vaccination campaigns. |
format | Online Article Text |
id | pubmed-8464022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84640222021-09-27 Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study Cassaniti, Irene Bergami, Federica Percivalle, Elena Gabanti, Elisa Sammartino, Josè Camilla Ferrari, Alessandro Adzasehoun, Kodjo Messan Guy Zavaglio, Federica Zelini, Paola Comolli, Giuditta Sarasini, Antonella Piralla, Antonio Ricciardi, Alessandra Zuccaro, Valentina Maggi, Fabrizio Novazzi, Federica Simonelli, Luca Varani, Luca Lilleri, Daniele Baldanti, Fausto Clin Microbiol Infect Original Article OBJECTIVES: To assess the humoral and cell-mediated response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited by the mRNA BNT162b2 vaccine in SARS-CoV-2-experienced and -naive subjects against a reference strain and SARS-CoV-2 variants. METHODS: The humoral response (including neutralizing antibodies) and T-cell-mediated response elicited by BNT162b2 vaccine in 145 healthcare workers (both naive and positive for previous SARS-CoV-2 infection) were evaluated. In a subset of subjects, the effect of SARS-CoV-2 variants on antibody level and cell-mediated response was also investigated. RESULTS: Overall, 125/127 naive subjects (98.4%) developed both neutralizing antibodies and specific T cells after the second dose of vaccine. Moreover, the antibody and T-cell responses were effective against viral variants since SARS-CoV-2 NT Abs were still detectable in 55/68 (80.9%) and 25/29 (86.2%) naive subjects when sera were challenged against β and δ variants, respectively. T-cell response was less affected, with no significant difference in the frequency of responders (p 0.369). Of note, two doses of vaccine were able to elicit sustained neutralizing antibody activity against all the SARS-CoV-2 variants tested in SARS-CoV-2-experienced subjects. CONCLUSIONS: BNT162b2 vaccine elicited a sustained humoral and cell-mediated response in immunocompetent subjects after two-dose administration of the vaccine, and the response seemed to be less affected by SARS-CoV-2 variants, the only exceptions being the β and δ variants. Increased immunogenicity, also against SARS-CoV-2 variant strains, was observed in SARS-CoV-2-experienced subjects. These results suggest that triple exposure to SARS-CoV-2 antigens might be proposed as valuable strategy for vaccination campaigns. European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-02 2021-09-25 /pmc/articles/PMC8464022/ /pubmed/34582981 http://dx.doi.org/10.1016/j.cmi.2021.09.016 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Cassaniti, Irene Bergami, Federica Percivalle, Elena Gabanti, Elisa Sammartino, Josè Camilla Ferrari, Alessandro Adzasehoun, Kodjo Messan Guy Zavaglio, Federica Zelini, Paola Comolli, Giuditta Sarasini, Antonella Piralla, Antonio Ricciardi, Alessandra Zuccaro, Valentina Maggi, Fabrizio Novazzi, Federica Simonelli, Luca Varani, Luca Lilleri, Daniele Baldanti, Fausto Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study |
title | Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study |
title_full | Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study |
title_fullStr | Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study |
title_full_unstemmed | Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study |
title_short | Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study |
title_sort | humoral and cell-mediated response against sars-cov-2 variants elicited by mrna vaccine bnt162b2 in healthcare workers: a longitudinal observational study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464022/ https://www.ncbi.nlm.nih.gov/pubmed/34582981 http://dx.doi.org/10.1016/j.cmi.2021.09.016 |
work_keys_str_mv | AT cassanitiirene humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT bergamifederica humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT percivalleelena humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT gabantielisa humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT sammartinojosecamilla humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT ferrarialessandro humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT adzasehounkodjomessanguy humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT zavagliofederica humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT zelinipaola humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT comolligiuditta humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT sarasiniantonella humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT pirallaantonio humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT ricciardialessandra humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT zuccarovalentina humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT maggifabrizio humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT novazzifederica humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT simonelliluca humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT varaniluca humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT lilleridaniele humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy AT baldantifausto humoralandcellmediatedresponseagainstsarscov2variantselicitedbymrnavaccinebnt162b2inhealthcareworkersalongitudinalobservationalstudy |